NextCure, Inc. — Form 8-K
Filed September 25, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 82/100
What the filing says
NextCure (market cap ~$12.6M) filed a Delaware Chancery Court petition on Sept 14, 2026 seeking judicial validation of a 1:12 reverse stock split (2025 Reverse Split Amendment) that became effective July 14, 2025. The split was approved by 64.76% of outstanding shares (18.2M votes for, 2.0M against, out of ~28M shares), meeting the "Votes Cast" standard under Delaware law. However, it fell short of the 66.67% supermajority required by the company's charter if that higher threshold applies to reverse splits. Subsequent Delaware law amendments (effective Aug 2026) created ambiguity about which voting standard governed. The company now faces uncertainty over share validity ahead of a planned merger with Avere Therapeutics (closing target: Nov 2026) and prior equity financings (Simcere, November PIPE, ATM offering totaling ~$14.5M) executed in reliance on split validity.
Why this rating
Existential threat: if 2025 split invalidated, capitalization structure collapses, prior financings and pending merger jeopardized, delisting risk, and stock ownership untraceable. Represents ~100% of current market value uncertainty.
Tradability signal
SHORT
conviction 32/100 · expected -0.88% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (30 in this cell) moved +1.61% in the called direction over 4 hrs; shrunk for sample size that's a +0.88% edge. Price is up 0.0% since the filing hit EDGAR — market hasn't digested it yet. Exit plan: HARD stop 5% against entry — default width (volatility unmeasured), fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $5.08 ▲ 0.00% | at our read · unknown $5.08 | +10 min · unknown $5.17 ▲ 1.77% | +30 min · unknown $5.04 ▼ 0.79% | +1 hr · unknown $5.03 ▼ 0.98% | +4 hrs · unknown $5.12 ▲ 0.79% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.